Results 241 to 250 of about 76,904 (360)

Combined Immediate‐Release and Extended‐Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation

open access: yesClinical Pharmacology in Drug Development, Volume 14, Issue 9, Page 717-727, September 2025.
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja   +8 more
wiley   +1 more source

A novel transgenic reporter of extracellular acidification in zebrafish elucidates skeletal muscle T‐tubule pH regulation

open access: yesDevelopmental Dynamics, Volume 254, Issue 9, Page 1068-1079, September 2025.
Abstract Disruption of extracellular pH and proton‐sensing can profoundly impact cellular and protein functions, leading to developmental defects. To visualize changes in extracellular pH in the developing embryo, we generated a zebrafish transgenic line that ubiquitously expresses the ratiometric pH‐sensitive fluorescent protein pHluorin2, tethered to
Leif R. Neitzel   +5 more
wiley   +1 more source

Protective Effects of Buckwheat and Isoquercitrin Against Noise‐Induced Hearing Loss in Mice: An Antioxidant Strategy Targeting the Nrf2/HO‐1 Pathway in Auditory Hair Cells

open access: yesFood Frontiers, Volume 6, Issue 5, Page 2422-2436, September 2025.
Isoquercitrin (IQ), a major bioactive compound in buckwheat (Fagopyrum esculentum Moench; BW), serves as a key mediator of the protective effects of BW against noise‐induced hearing loss (NIHL) by activating the Nrf2/HO‐1 signaling pathway, and oral administration of BW and IQ significantly attenuates oxidative stress and hair cell apoptosis through ...
Hojin Lee   +6 more
wiley   +1 more source

Outcomes and Adverse Events of WHO Shorter Regimen in the Treatment of Multi‐Drug Resistant Tuberculosis in Bhutan: A Longitudinal Study

open access: yesHealth Science Reports, Volume 8, Issue 9, September 2025.
ABSTRACT Background and Aims Bhutan first introduced the Shorter Regimen, consisting of a combination of Amikacin, Clofazamine, Ethionamide, Ethambutol, high dose Isoniazid, Moxifloxacin and Pyrazinamide, for the treatment of rifampicin or multidrug resistant tuberculosis (RR/MDR‐TB) in 2018.
Gaki Nima   +3 more
wiley   +1 more source

Cochlear Implantation Outcomes in Genotyped Subjects with Sensorineural Hearing Loss. [PDF]

open access: yesJ Assoc Res Otolaryngol
Fehrmann MLA   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy